Controlled Substances Act provisions relating to the distribution of medication assisted therapies (The Protecting Patient Access to Emergency Medications Act, S. 916/H.R. 304. Adequacy of funding for opioid overuse disorder (OUD) treatment in the Affordable Care Act Repeal/Replace legislation.
Duration: July 15, 2015
to
September 30, 2017
General Issues: Health Issues
Spending: about $270,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Natl Drug Control Policy (NDCP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Patricia Knight Chief of Staff, Sen. Orrin Hatch; Health Policy Dir, Sen. Orrin Hatch
Chief of Staff, Sen. Orrin G. Hatch
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2017
Knight Capitol Consultants terminated an engagement in which they represented Braeburn Pharmaceuticals, Inc. on Sept. 29, 2017.
Original Filing: 300900951.xml
Lobbying Issues
Controlled Substances Act provisions relating to the distribution of medication assisted therapies (The Protecting Patient Access to Emergency Medications Act, S. 916/H.R. 304. Adequacy of funding for opioid overuse disorder (OUD) treatment in the Affordable Care Act Repeal/Replace legislation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300891051.xml
Lobbying Issues
Controlled Substances Act provisions relating to the distribution of medication assisted therapies (The Protecting Patient Access to Emergency Medications Act, S. 916/H.R. 304. Adequacy of funding for opioid overuse disorder (OUD) treatment in the Affordable Care Act Repeal/Replace legislation (no bill numbers). Adequacy of reimbursement for innovative medications to treat OUD.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on April 12, 2017.
Original Filing: 300864413.xml
Lobbying Issues
Controlled Substances Act provisions relating to the distribution of medication assisted therapies (no specific bill)
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856116.xml
Lobbying Issues
Issues related to the treatment of opioid addiction, including: PL 114-198, the Comprehensive Addiction Recovery Act (CARA) and its implementation, limits on physician prescribing of treatments for opioid addiction, and adequacy of reimbursement for such treatments. Possible changes to the Controlled Substances Act regarding distribution of treatments for opioid abuse.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300839126.xml
Lobbying Issues
Issues related to the treatment of opioid addiction, including: PL 114-198, the Comprehensive Addiction Recovery Act (CARA) and its implementation; S. 1893, Mental Health Awareness and Improvement Act of 2015; H.R. 3691, Improving Treatment for Pregnant and Postpartum Women Act; H.R. 3680, Co-Prescribing to Reduce Overdoses Act of 2015; H.R. 2536/S.1455, the Recovery Enhancement for Addiction Treatment Act; H.R. 2805; the Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015; and H.R. 2872, the Opioid Addiction Treatment Modernization Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300818975.xml
Lobbying Issues
Issues related to the treatment of opioid addiction, including: S. 524, the Comprehensive Addiction Recovery Act (CARA) and amendments thereto; S. 1893, Mental Health Awareness and Improvement Act of 2015; H.R. 3691, Improving Treatment for Pregnant and Postpartum Women Act; H.R. 3680, Co-Prescribing to Reduce Overdoses Act of 2015; H.R. 2536/S.1455, the Recovery Enhancement for Addiction Treatment Act; H.R. 2805; the Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015; and H.R. 2872, the Opioid Addiction Treatment Modernization Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300796565.xml
Lobbying Issues
Issues related to the treatment of opioid addiction, including: S. 524, the Comprehensive Addiction Recovery Act (CARA) and amendments thereto; S. 1893, Mental Health Awareness and Improvement Act of 2015; H.R. 3691, Improving Treatment for Pregnant and Postpartum Women Act; H.R. 3680, Co-Prescribing to Reduce Overdoses Act of 2015; H.R. 2536/S.1455, the Recovery Enhancement for Addiction Treatment Act; H.R. 2805; the Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015; and H.R. 2872, the Opioid Addiction Treatment Modernization Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781940.xml
Lobbying Issues
Issues related to the treatment of opioid addiction, including: S. 799, Protecting Our Infants Act; S. 1893 Mental Health Awareness and Improvement Act of 2015; H.R. 3691, Improving Treatment for Pregnant and Postpartum Women Act; H.R. 3680, Co-Prescribing to Reduce Overdoses Act of 2015; H.R. 2536/S.1455, the Recovery Enhancement for Addiction Treatment Act; H.R. 2805; the Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015; and H.R. 2872, the Opioid Addiction Treatment Modernization Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Knight Capitol Consultants lobbied for Braeburn Pharmaceuticals, Inc. , earning $30,000. The report was filed on Oct. 22, 2015.
Original Filing: 300766372.xml
Lobbying Issues
Issues related to the treatment of opioid addiction, including: S. 799, Protecting Our Infants Act; S. 1893 Mental Health Awareness and Improvement Act of 2015; H.R. 3691, Improving Treatment for Pregnant and Postpartum Women Act; H.R. 3680, Co-Prescribing to Reduce Overdoses Act of 2015; H.R. 2536/S.1455, the Recovery Enhancement for Addiction Treatment Act; H.R. 2805; the Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015; and H.R. 2872, the Opioid Addiction Treatment Modernization Act.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...